ERBB2 and breast cancer: An ongoing clinical trial (NCT03112590) aims to elucidate how augmenting the Th1 response can be a pivotal immunotherapeutic tool, by testing a combination of IFN-γ with paclitaxel, trastuzumab, and pertuzumab in HER2+ BC.